Researchers at the University of Queensland have initiated a groundbreaking clinical trial to evaluate ASITI-201, an investigational immunotherapy designed to treat type 1 diabetes (T1D). Developed under the leadership of Professor Ranjeny Thomas, ASITI-201 combines a pancreatic protein with vitamin D to modulate the immune system, aiming to protect insulin-producing beta cells from autoimmune destruction. The trial has commenced with five adult participants recently diagnosed with T1D, focusing on preserving residual pancreatic function and potentially reducing insulin dependency. This first-in-human study builds upon successful preclinical results and is supported by funding from the Medical Research Future Fund, Breakthrough T1D, and the Helmsley Charitable Trust. The findings from this trial may pave the way for larger studies, including those involving pediatric populations, and represent a significant step toward innovative, immune-targeted therapies for T1D.
🧬 Not sure where to start? Try searching for your diagnosis above or visit the “Diseases” section.
